Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

9.670 +0.070 (+0.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,620,730
Open 9.960
Bid (Size) 9.500 (1)
Ask (Size) 9.650 (4)
Prev. Close 9.600
Today's Range 9.380 - 10.13
52wk Range 6.330 - 19.97
Shares Outstanding 68,995,606
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders
Editas Medicine Inc (NASDAQ: EDIT) annou 
Via Benzinga
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
From Editas Medicine, Inc.
Via GlobeNewswire

Performance

YTD
+14.57%
+14.57%
1 Month
-5.89%
-5.89%
3 Month
+17.93%
+17.93%
6 Month
-3.11%
-3.11%
1 Year
-24.86%
-24.86%

More News

Read More
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
Via InvestorPlace
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine's Return On Capital Employed Insights
Via Benzinga
6 Analysts Have This to Say About Editas Medicine
Via Benzinga
Editas Medicine: Q1 Earnings Insights
Via Benzinga
Preview: Editas Medicine's Earnings
Via Benzinga
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
Via Benzinga
7 Short-Squeeze Stocks Set for a May Rally
Via InvestorPlace
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
Via The Motley Fool
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
From Editas Medicine, Inc.
Via GlobeNewswire
2 Stocks Under $15 Per Share to Consider
Via The Motley Fool
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
From Editas Medicine, Inc.
Via GlobeNewswire
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Earnings Scheduled For May 5, 2023
Via Benzinga
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
The 3 Most Promising Gene Editing Stocks to Buy in 2023
Via InvestorPlace
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Why Shares of Editas Medicine Rose Monday
Via The Motley Fool
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.